Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone

Bone

Volumn 44, Issue 4, 2009, Pages 634-638

  Zikan, Vit ^a   Stepan, Jan J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Aminobisphosphonates; Bone resorption; Hypocalcemia; Parathyroid hormone; Raloxifene

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; CALCIUM ION; CARBOXY TERMINAL TELOPEPTIDE; EDETIC ACID; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; HYPOCALCEMIA; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; VITAMIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ALENDRONATE; AREA UNDER CURVE; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; BONE RESORPTION; CHELATING AGENTS; COLLAGEN TYPE I; EDETIC ACID; ETIDRONIC ACID; FEMALE; HUMANS; HYPOCALCEMIA; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PEPTIDES; RALOXIFENE;

EID: 61749083269     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.12.013     Document Type: Article

References (24)

1. Delmas P.D. Treatment of postmenopausal osteoporosis. Lancet 359 (2002) 2018-2026
2. Ma Y.L., Cain R.L., Halladay D.L., Yang X., Zeng Q., Miles R.R., et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142 (2001) 4047-4054
3. Martin T.J., and Sims N.A. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol. Med. 11 (2005) 76-81
4. Zikán V., and Štěpán J.J. Marker of bone resorption in acute response to exogenous or endogenous parathyroid hormone. Biomark. Insights 3 (2008) 19-24
5. Lindsay R., Cosman F., Zhou H., Bostrom M.P., Shen V.W., Cruz J.D., et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J. Bone Miner. Res. 21 (2006) 366-373
6. Cosman F., Nieves J., Woelfert L., Shen V., and Lindsay R. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J. Bone Miner. Res. 13 (1998) 1051-1055
7. Finkelstein J.S., Leder B.Z., Burnett S.A., Wyland J.J., Lee H., de la Paz A.V., et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J. Clin. Endocrinol. Metab. 91 (2006) 2882-2887
8. Miller P., Lindsay R., Watts N., Meeves S., Lang T., Delmas P., et al. Patients previously treated with risedronate demonstrate greater responsiveness to teriparatide than those previously treated with alendronate: the OPTAMISE study. J. Bone Miner. Res. 22 (2007) S26
9. Boonen S., Marin F., Obermayer-Pietsch B., Simoes M.E., Barker C., Glass E.V., et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 93 (2008) 852-860
10. Black D.M., Greenspan S.L., Ensrud K.E., Palermo L., McGowan J.A., Lang T.F., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349 (2003) 1207-1215
11. Ettinger B., San Martin J., Crans G., and Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J. Bone Miner. Res. 19 (2004) 745-751
12. Delmas P., Watts N., Miller P., Cahall D., Bilezikian J., and Lindsay R. Bone turnover markers demonstrate greater earlier responsiveness to teriparatide following treatment with risedronate compared with alendronate: the OPTAMISE study. J. Bone Miner. Res. 22 (2007) S27
13. Stepan J.J., Dobnig H., Burr D.B., Li J., Ma Y.L., Sipos A., et al. Histomorphometric changes by teriparatide in alendronate pre-treated women with osteoporosis. J. Bone Miner. Res. 23 (2008) S6-7
14. Onyia J.E., Miles R.R., Yang X., Halladay D.L., Hale J., Glasebrook A., et al. In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J. Bone Miner. Res. 15 (2000) 863-871
15. Holtrop M.E., King G.J., Cox K.A., and Reit B. Time-related changes in the ultrastructure of osteoclasts after injection of parathyroid hormone in young rats. Calcif. Tissue Int. 27 (1979) 129-135
16. Lindsay R., Nieves J., Henneman E., Shen V., and Cosman F. Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients. J. Clin. Endocrinol. Metab. 77 (1993) 1535-1539
17. Schwietert H.R., Groen E.W., Sollie F.A., and Jonkman J.H. Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers. Clin. Pharmacol. Ther. 61 (1997) 360-376
18. Gooi J.H., Quinn J.M.W., Gillespie M.T., Karsdal M.A., Martin T.J., and Sims N.A. Calcitonin attenuates the anabolic effect of PTH in young rats. J. Bone Miner. Res. 21 (2006) S197
19. Idris A.I., Rojas J., Greig I.R., Van't Hof R.J., and Ralston S.H. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif. Tissue Int. 82 (2008) 191-201
20. Landman J.O., and Papapoulos S.E. Uninterrupted oral bisphosphonate (pamidronate) therapy of patients with osteoporosis is not associated with chronic stimulation of parathyroid hormone secretion. Osteoporos Int. 5 (1995) 93-96
21. Cosman F., Nieves J., Horton J., Shen V., and Lindsay R. Effects of estrogen on response to edetic acid infusion in postmenopausal osteoporotic women. J. Clin. Endocrinol. Metab. 78 (1994) 939-943
22. Oleksik A., Duong T., Popp Snijders C., Pliester N., Asma G., and Lips P. Effects of the selective oestrogen receptor modulator-raloxifene-on calcium and PTH secretory dynamics in women with osteoporosis. Clin. Endocrinol. (Oxf) 54 (2001) 575-582
23. Eastell R., McCloskey E.V., Glover S., Rogers A., Garnero P., Lowery J., et al. Rapid and robust biochemical response to teriparatide therapy for osteoporosis. J. Bone Miner. Res. 22 (2007) S322
24. Rude R.K., Oldham S.B., and Singer F.R. Functional hypoparathyroidism and parathyroid hormone end-organ resistance in human magnesium deficiency. Clin. Endocrinol. (Oxf) 5 (1976) 209-224